Ashland (ASH) Q3 2026 earnings summary

Executive summary

• Sales increased 7% year-over-year to $497 million, with volume gains across all business units and regions, led by Life Sciences and Personal Care; operational improvements and pricing actions supported profitability.

• Adjusted EBITDA was $109 million (21.9% margin), down 4% from the prior year, reflecting margin compression in Specialty Additives and Intermediates, but strong performance in Life Sciences and Personal Care.

• Net income for Q3 2026 was $16 million, reversing a prior year net loss, with diluted EPS of $0.35; adjusted EPS (excluding amortization) was $1.02.

• Free cash flow remained strong at $103 million, supported by disciplined inventory management and operational improvements.

• Announced a cooperation agreement with Ancora, adding two independent directors and forming a capital allocation advisory committee.

Financial highlights

• Gross profit margin was 34.8%, down 40 bps year-over-year; adjusted EBITDA margin was 21.9%, down from 24.4% in the prior-year quarter.

• Operating income was $63 million, down 3% year-over-year; adjusted operating income was $63 million, down from $65 million last year.

• Free cash flow conversion was above 90% for the quarter; ongoing free cash flow conversion expected to exceed 50% of adjusted EBITDA.

• Ended the quarter with $936 million in liquidity and net leverage of 2.4x, within the long-term target range.

• Dividend increased annually since 2009; $520 million remains under $1 billion share repurchase authorization.

Outlook and guidance

• Full-year 2026 sales guidance reaffirmed at $1,835–$1,870 million; adjusted EBITDA guidance at $385–$400 million.

• Adjusted EPS outlook revised to low- to mid-single digit growth due to a higher tax rate.

• Ongoing free cash flow conversion expected to exceed 50% of adjusted EBITDA, with capital expenditures projected at ~$90 million.

• Sequential improvement expected in Q4 as operational performance and pricing actions continue to gain traction.

• Key market risks include geopolitical instability, Chinese overcapacity, and FX volatility.